RESEARCH TRIANGLE PARK, N.C., Aug. 23 /PRNewswire-FirstCall/ --
Biotechnology company Icoria, Inc. (OCTBB: ICOR.OB) today announced that it
has signed an agreement with Isis Pharmaceuticals to identify biomarkers of
toxicity in animal models. Icoria will use its metabolomics platform to
characterize differences in biochemical profiles between treated and untreated
animal subjects and to identify those biochemicals that are specifically
affected by treatment. Isis can use this information to suggest pathways that
may be altered by future drug candidates.
Metabolomics, or biochemical profiling, uses mass spectrometry to measure
net changes in the level of the body's endogenous biochemicals, such as amino
acids, sugars and fatty acids, and provides a means of evaluating drug action
and disease state. When combined with proprietary software developed by
Icoria, this technology enables Icoria to construct biomarkers that can detect
toxicity or the therapeutic effects of drugs. Drug development companies such
as Isis can use this data to infer pathway-based mechanisms of drug action and
patient response, and to assess drug safety.
Financial details of the agreement were not disclosed, however, it is not
expected to significantly impact the company's recently released financial
statements.
About Icoria
Icoria, Inc. is a biotechnology company focused on the discovery of novel,
multi-parameter biomarkers using its unique multi-platform approach. Icoria
intends to use these future biomarkers internally to develop multi-analyte
diagnostics to define and grade pathology or disease state with a high level
of specificity and sensitivity, and use its technology to help collaborators
and customers develop better, safer drugs and diagnostics and to identify
targets, leads and drug/diagnostic combinations for liver injury, metabolic
disorders and cancer. Icoria's shares trade on the over the counter bulletin
board.
This press release contains forward-looking statements including, but not
limited to, the Company's expectations for its healthcare based business model
and its biomarker discovery platform. Such forward-looking statements are
based on management's current expectations and are subject to a number of
risks, factors and uncertainties that may cause actual results, events and
performance to differ materially from those referred to in the forward-looking
statements. These risks, factors and uncertainties include, but are not
limited to, Icoria's ability to identify biomarkers, early stage of
development, history of net losses, technological and product development
uncertainties, reliance on research collaborations, uncertainty of additional
funding and ability to protect its patents and proprietary rights. Certain of
these and other risks are identified in Icoria's Quarterly Reports on Form
10-Q for the periods ended June 30, 2005, March 31, 2005, as amended, and its
Annual Report on Form 10-K for the year ended December 31, 2004, all as filed
with the Securities and Exchange Commission. The Company does not intend to
update any of the forward-looking statements after the date of this release to
conform these statements to actual results or to changes in our expectations,
except as may be required by law.
SOURCE Icoria, Inc.
 back to top
Related links:
http://www.icoria.com
CONTACT:
Media - Public Relations of Icoria, Inc.,
+1-919-425-2999
|
